

# REFERENCE NO.

92

In re application of: Singh, Nikhilesh, et al.

Application No.: 10/763,641

Filing Date: January 22, 2004

Attorney Docket No.: 022205-000110US

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 31/505, 31/445, 31/435, 31/495, 9/00</b>		A1	(11) International Publication Number: <b>WO 98/42344</b>
			(43) International Publication Date: 1 October 1998 (01.10.98)
(21) International Application Number: PCT/GB98/00885			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 24 March 1998 (24.03.98)			
(30) Priority Data: 9706089.1 24 March 1997 (24.03.97) GB			
(71) Applicant (for all designated States except US): R. P. SCHERER LIMITED [GB/GB]; Frankland Road, Blagrove, Swindon, Wiltshire SN5 8YS (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): GREEN, Richard, David [GB/GB]; 4 Bridge Street, Manton, Marlborough, Wiltshire SN8 4HR (GB). JOHNSON, Edward, Stewart [GB/GB]; Willow Vale, Castle End Road, Ruscombe, Berkshire RG10 9XG (GB). LACY, Jonathan, Ernest [GB/GB]; 36 Home Close, Chiseldon, Swindon SN4 0ND (GB). MALLARD, Nicholas, John [GB/GB]; 122 Clayfield, Brimsham Park, Yate, Bristol BS17 5HU (GB).			
(74) Agent: WALLACE, Sheila, Jane; Lloyd Wise Tregear & Co., Commonwealth House, 1-19 New Oxford Street, London WC1A 1LW (GB).			<b>Published</b> <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PHARMACEUTICAL COMPOSITION			
(57) Abstract <p>This invention relates to a pharmaceutical composition for oral administration comprising a carrier and, as an active ingredient, a 5-HT<sub>1</sub> agonist, characterised in that the composition is formulated to reduce pre-systemic metabolism of said 5-HT<sub>1</sub> agonist. A process for preparing such a composition and the use of such a composition for the treatment of anxiety, depression, attention deficit disorder and/or panic disorders and/or as a memory enhancer are also provided.</p>			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

-1-

PHARMACEUTICAL COMPOSITION

This invention relates to a pharmaceutical  
5 composition, a process for preparing such a composition  
and the use of such a composition for the treatment of  
anxiety, depression, attention deficit disorder and/or  
panic disorders, sleep apnoea and/or related respiratory  
disorders and/or substance addiction, especially alcohol  
10 abuse, the treatment and/or prophylaxis of incontinence  
disorders, inducing immunosuppression and/or treating  
immune disorders, the alleviation of extrapyramidal motor  
disorders and/or as a memory enhancer.

Buspirone (8-[4-[4-(2-pyrimidinyl)-1-  
15 piperazinyl]butyl]-8-azaspiro[4.5]decane-7,9-dione) has  
been shown to be effective in the treatment of anxiety.  
The mechanism of action of buspirone has not been fully  
elucidated. However, it is known that buspirone is a 5-  
HT<sub>1</sub> agonist and, in particular, a potent 5-HT<sub>1A</sub> agonist  
20 and it is thought that it is action at these receptors  
which may account for its anxiolytic activity.

Buspirone is currently administered orally in the  
form of a conventional tablet which is scored in a manner  
which provides for it to be broken into halves or thirds  
25 along breaklines, thus allowing for some titration of the  
dose. However, each tablet or portion thereof is  
designed to be swallowed whole. Doses range from 15 to  
60 mg per day and may be delivered as 2 or 3 divided  
doses. When administered in this way, buspirone is  
30 absorbed from the gastrointestinal tract, that is, the  
stomach, the small intestine and the proximal large  
intestine (colon), into the hepatic portal system and is  
presented to the liver before reaching the systemic  
circulation. The liver is known to be the principal site  
35 for conversion of active buspirone into metabolites and,  
indeed, buspirone is rapidly metabolised by the liver  
into a large number of metabolites. In a radio-label

-2-

study in man, twelve metabolites of buspirone were isolated from urine (see H. K. Jajoo et al, Drug Metabolism and Disposition, (1989), 17, 634-640). However, only one of these metabolites, 1-  
5 pyrimidinylpiperazine (1-PP), has been reported to possess any potential therapeutic activity and this compound is said to possess, at most, only 20% of the activity of unchanged buspirone as determined by the Vogel conflict test in rats (see R.E. Gammans et al,  
10 Am.J.Med., (1986), 80(suppl.3B), 41-51).

The mean systemic availability of unchanged buspirone is thought to be about 4% after conventional oral administration and the plasma levels of this drug are said to exhibit great variability. This latter  
15 effect has been attributed to differences between individuals in pre-systemic metabolism, that is, metabolism in the gastrointestinal tract, in the membranes lining the gastrointestinal tract and also in the liver. However, it is clear that the clinical  
20 effectiveness of buspirone is compromised by the extensive pre-systemic metabolism of this drug which occurs following conventional oral administration.

Buspirone is an example from a class of compounds known as the azapirones which have been shown to be  
25 effective in the treatment of anxiety. Other azapirones include 4,4-dimethyl-1-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-2,6-piperidinedione (gepirone), 2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide (ipsapirone),  
30 (3a $\alpha$ , 4 $\alpha$ , 4a $\beta$ , 6a $\beta$ , 7 $\alpha$ , 7a $\alpha$ )-3a, 4, 4a, 6a, 7, 7a-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-etheno-1H-cyclobut[f]isoindole-1,3(2H)-dione (zalospirone),  
3-butyl-7-[4-[4-(2-methoxyphenyl)-1-piperazinyl]butyl]-  
9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane-2,4,6,8-  
35 tetrone (umespirone), (S)-8-[4-[(3,4-dihydro-5-methoxy-2H-1-benzopyran-3-yl)propylamino]butyl]-8-azaspiro[4.5]decane-7,9-dione (alnespirone), 6-(3-

- 3 -

chlorophenoxy)-2-methyl-1-oxa-4-azaspiro[4.5]decan-3-one (enilospirone), octahydro-3-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,5-methano-6,7,9-metheno-1H-pentaleno [1,2-d]azepine-2,4(3H,5H)-dione (WY-48723), 4-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,4-benzoxazepine-3,5(2H,4H)-dione (SUN-8399), (3 $\alpha$ ,4 $\beta$ ,7 $\beta$ ,7 $\alpha$ )-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-methano-1H-isoindole-1,3(2H)-dione 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (tandospirone) and salts thereof. All these compounds act as agonists at 5-HT<sub>1</sub> receptors, particularly 5-HT<sub>1A</sub> receptors, and, like buspirone, are subject to extensive pre-systemic metabolism. Other compounds which interact with 5-HT<sub>1</sub> receptors (5-HT<sub>1</sub> agonists) include

(+) -N-[2-[4-[2,3-dihydro-2-(hydroxymethyl)-1,4-benzodioxin-5-yl]-1-piperazinyl]ethyl]-4-fluorobenzamide (flesinoxan), 2-[4-[4-(4-chloro-1H-pyrazol-1-yl)butyl]-1-piperazinyl]pyrimidine (lesopitron), (R)-3,4-dihydro-N-(1-methylethyl)-3-((1-methylethyl)propylamino)-2H-1-benzopyran-5-carboxamide (ebalzotan), N-[2-[4-(2-pyrimidinyl)-1-piperazinyl]]adamantane-1-carboxamide (adatanserin), (R)-4-(dipropylamino)-1,3,4,5-tetrahydro-benz(cd)indole-6-carboxamide (LY-228729), F-8910-RS, (-)-cis-3-propyl-2,3,3a(R),4,5,9b-hexahydro-14-benz[e]indole-9-carboxamide (U-93385), 4-[2-[4-(naphthalen-1-yl)piperazin-1-yl]ethyl]quinolin-2(1H)one (SL-87.0765), 2-[4-[4,4-bis(4-fluorophenyl)butyl]-1-piperazinyl-3-pyridinecarboxylic acid methyl ester (FG-5893), 4-fluoro-N-[2-[4-[7-methoxy-1-naphthyl]piperazin-1-yl]ethyl]benzamide (S-14506), 5-methoxy-3-[4-(4-(4-methoxyphenyl)-1-piperazinyl)butyl]indole (EMD-56551), (-)-N-[2-(8-methyl-1,4-benzodioxan-2-ylmethylamino)ethyl]adamantane-1-carboxamide (HT-90B), F-92502-CN, 2-[4-[4-(4-nitropyrazol-1-yl)butyl]piperazin-1-yl]pyrimidine (E-4414), 5-[3-[[2S]-1,4-benzodioxan-2-ylmethyl]-amino]propoxy]-1,3-benzodioxolane (MKC-242), 4-methyl-2-

-4-

- [4-(4-(pyrimidin-2-yl)-piperazino)butyl]-2H,4H-1,2,4-triazin-3,5-dione (F-12439), 1-(2-(4-(3-trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol-  
[1H]-2-one (BIMT-17), LY-39, SL-88.0338, 1,2,3,6-  
5 tetrahydro-1-[2-(2-naphthalenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]pyridine (SR-57746A), 1-(9H-fluoren-2-yl)-2-(1H-imidazol-1-yl)ethanone (LY-175644),  
(+/-)trans-2-(4-(3a,4,4a,6a,7,7a-hexahydro-4,7-etheno-1H-cyclobut[f]isoindol-1,3-dionyl)butyl-9-methoxy-  
10 2,3,3a,4,5,9b-hexahydro-1H-benz[e]isoindole (A-74283),  
1,3,4,5-tetrahydro-6-methoxy-N,N-dipropylbenz[cd]indol-4-amine (Bay-r-1531), 4-(4-methyl-1-piperazinyl)-7-(trifluoromethyl)-pyrrolo[1,2-a]quinoxaline (Z)-2-butenedioate (1:2) (CGS-12066B), trans-1,3,4,4a,5,10b-  
15 hexahydro-10-methoxy-4-propyl-2H-[1]benzopyrano[3,4-b]pyridine (CGP-50281), N-propyl-N-[2-(4-fluorobenzamido)ethyl]amino-5,6,7,8-tetrahydroquinoline (WAY-100012), 3a,4,4a,6a,7,7a-hexahydro-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-4,7-ethenocyclobuta[f]-  
20 1,2-benzisothiazol-3(2H)-one 1,1-dioxide, cis-7-chloro-10-methoxy-5a,10b-dihydro-3N-n-propyl-6H-indeno[1,2-d]azepine, 1-cyclohexyl-3-[4-[4-(2,3-dihydro-2,2-dimethylbenzofuran-7-yl)-1-piperazinyl]-1-butyl]-2-imidazolidinone, 1-[3-amino-2H-1-benzopyran-2-one-8-yl]piperazine, 4-(1-methylethyl)-2-[3-(trifluoromethyl)-phenyl]morpholine (oxaflozane), N,5-dimethyl-10-dibenz-(b,f)azepine-ethanamine (RU-5031), 1,4-dihydro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-5H-pyrrolo[3,2-b]-pyridin-5-one (CP-93129), N-methyl-3-(1-methyl-4-piperidinyl)-1H-indole-5-ethanesulphonamide  
25 (naratriptan), 3-[3-[4-(5-methoxy-4-pyrimidinyl)-1-piperazinyl]propyl]-N-methyl-1H-indole-5-methanesulphonamide (avitriptan), N,N-dimethyl-5-(1H-1,2,4-triazol-1-yl)methyl-1H-indole-3-ethanamine  
30 (rizatriptan), N-[4-[[5-[3-(2-aminoethyl)-1H-indol-5-yl]-1,2,4-oxadiazol-3-yl]methyl]phenyl]methanesulphonamide (L-694247), IS-159, 1-(((3-(2-(dimethylamino)ethyl)-1H-

-5-

indol-5-yl)methyl)sulphonyl)pyrrolidine (almotriptan),  
4-((3-(2-(dimethylamino)ethyl)-1H-indol-5-yl)methyl-(S)-  
2-oxazolidinone (zolmitriptan), 3-[2-(dimethylamino)-  
ethyl]-N-methyl-1H-indole-5-methanesulphonamide  
5 (sumatriptan), 3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-  
(phenylsulphonyl)ethyl)-(R)-1H-indole (eletriptan),  
(R)-(+)-3-(methylamino)-1,2,3,4-tetrahydro-9H-carbazole-  
6-carboxamide (VML-251), L-0076, ALX-0625,  
(R)-N-methyl-[3-(1-methyl-2-pyrrolidinyl)-1H-indol-5-  
10 yl)methanesulphonamide (CP-122288), 3-[3-[4-(5,6-  
dimethoxypyrimidin-4-yl)piperazin-1-yl]propyl]-N-methyl-  
1H-indol-5-yl-methylsulphonamide (VS-395), L-747201,  
LY-334370 and salts thereof.

It would be highly desirable from a clinical  
15 point of view to find a way of administering such 5-HT<sub>1</sub>  
agonists so that the bioavailability of the active  
ingredient is enhanced and the variability in plasma  
levels caused by differences in pre-systemic metabolism  
is reduced.

20 According to the present invention there is  
therefore provided a pharmaceutical composition for oral  
administration comprising a carrier and, as an active  
ingredient, a 5-HT<sub>1</sub> agonist, characterised in that the  
composition is formulated to reduce pre-systemic  
25 metabolism of the 5-HT<sub>1</sub> agonist.

If pre-systemic metabolism of the active  
ingredient is to be reduced, it is important that the  
active ingredient is absorbed into the systemic  
circulation at a site which enables the active ingredient  
30 to avoid entering the portal circulation to the liver and  
thus avoid extensive metabolism by the liver (the so-  
called "first pass effect"). Since absorption from the  
gastrointestinal tract is known to result in the active  
ingredient entering the hepatic portal system to the  
35 liver, one option for reduction of pre-systemic  
metabolism is to promote absorption from sites before the  
active ingredient reaches the gastrointestinal tract.

-6-

Accordingly, it is preferred that the composition of the invention is formulated to promote pre-gastric absorption of the 5-HT<sub>1</sub> agonist.

5 The term "pre-gastric absorption" is used to refer to absorption of the active ingredient from that part of the alimentary canal prior to the stomach and includes buccal, sublingual, oropharyngeal and oesophageal absorption.

10 It is envisaged that such pre-gastric absorption will occur primarily across the mucous membranes in the mouth, pharynx and oesophagus. Accordingly, it is preferred that the composition of the invention is formulated to promote absorption of the active ingredient through the buccal, sublingual, pharyngeal and/or  
15 oesophageal mucous membranes.

It is therefore preferred that the composition of the invention should be in a form which sustains the active ingredient in contact with the buccal, sublingual, pharyngeal and/or oesophageal mucous membranes.

20 Preferably, the composition of the invention is in the form of a viscous emulsion, syrup or elixir, a sub-lingual tablet, a suckable or chewable tablet, softgel, lozenge, aqueous or non-aqueous drops or other dosage form designed to release the active ingredient in  
25 a controlled manner to saliva or to the buccal, pharyngeal and/or oesophageal mucous membranes, a fast-dispersing dosage form designed rapidly to release the active ingredient in the oral cavity, or a bioadherent system.

30 The term "bioadherent system" refers to a solid or liquid dosage form which, at body temperature, exhibits controlled release and bioadherence characteristics. This type of dosage form may be an emulsion which is water in oil in nature and whose  
35 internal phase is greater than that of the external phase. Examples of such bioadherent systems may be found in U.S. Patent No. 5055303.

-7-

Of the dosage forms listed above, fast-dispersing dosage forms are particularly preferred since they will disintegrate rapidly in the mouth without the need for water, or other liquid, to aid swallowing. Such fast-dispersing dosage forms are therefore more convenient and easier for patients to take than conventional oral dosage forms. Also, since no water, or other liquid, is required to take such fast-dispersing dosage forms, the active ingredient is presented for absorption at a higher concentration than with conventional oral dosage forms. Thus, use of such fast-dispersing dosage forms may allow a reduction in the dose required to achieve the desired therapeutic effect which, in turn, may result in a reduction in the incidence and/or severity of side effects. More reproducible plasma levels of the active ingredient may also be achieved with such dosage forms.

Since such fast-dispersing dosage forms produce a concentrated solution of the active ingredients in the saliva of the mouth, it is also possible that, when swallowed, this concentrated solution coats the stomach mucosa more effectively than a conventional drug dissolved in water and this may increase the rate of absorption of the active ingredient. Moreover, absorption from the highest part of the stomach may also by-pass the hepatic portal vein and hence produce a higher level of the active ingredient in the plasma.

One example of a fast-dispersing dosage form is described in U.S. Patent No. 4855326 in which a melt spinnable carrier agent, such as sugar, is combined with an active ingredient and the resulting mixture spun into a "candy-floss" preparation. The spun "candy-floss" product is then compressed into a rapidly dispersing, highly porous solid dosage form.

U.S. Patent No. 5120549 discloses a fast-dispersing matrix system which is prepared by first solidifying a matrix-forming system dispersed in a first solvent and subsequently contacting the solidified matrix

-8-

with a second solvent that is substantially miscible with the first solvent at a temperature lower than the solidification point of the first solvent, the matrix-forming elements and active ingredient being

5 substantially insoluble in the second solvent, whereby the first solvent is substantially removed resulting in a fast-dispersing matrix.

U.S. Patent No. 5079018 discloses a fast-dispersing dosage form which comprises a porous skeletal  
10 structure of a water soluble, hydratable gel or foam forming material that has been hydrated with water, rigidified in the hydrated state with a rigidifying agent and dehydrated with a liquid organic solvent at a temperature of about 0°C or below to leave spaces in place  
15 of hydration liquid.

Published International Application No. WO 93/12769 (PCT/JP93/01631) describes fast-dispersing dosage forms of very low density formed by gelling, with agar, aqueous systems containing the matrix-forming  
20 elements and active ingredient, and then removing water by forced air or vacuum drying.

U.S. Patent No. 5298261 discloses fast-dispersing dosage forms which comprise a partially collapsed matrix network that has been vacuum-dried above the collapse  
25 temperature of the matrix. However, the matrix is preferably at least partially dried below the equilibrium freezing point of the matrix.

Published International Application No. WO 91/04757 (PCT/US90/05206) discloses fast-dispersing  
30 dosage forms which contain an effervescent disintegration agent designed to effervesce on contact with saliva to provide rapid disintegration of the dosage form and dispersion of the active ingredient in the oral cavity.

U.S. Patent No. 5595761 discloses a particulate  
35 support matrix for use in making a rapidly dissolving tablet, comprising;

a first polypeptide component having a net charge

-9-

when in solution, e.g. non-hydrolysed gelatin;

a second polypeptide component having a net charge of the same sign as the net charge of the first polypeptide component when in solution e.g. hydrolysed gelatin; and

5 a bulking agent, and wherein the first polypeptide component and the second polypeptide component together comprise about 2% to 20% by weight of the particulate support matrix and wherein the bulking agent comprises about 60% to 96% by weight of the particulate support matrix; and

10 wherein the second polypeptide component has a solubility in aqueous solution greater than that of the first polypeptide component and wherein the mass: mass ratio of the first polypeptide component to the second polypeptide component is from about 2 : 1 to about 1 : 14; and

15 wherein when the support matrix is introduced into an aqueous environment the support matrix is disintegrable within less than about 20 seconds.

20 US Patent No. 5576014 discloses fast-dispersing dosage forms which dissolve intrabuccally and which comprise compressed moldings formed from granules comprising a saccharide having low moldability which has been granulated with a saccharide having high moldability. The resulting compressed moldings show quick disintegration in the buccal cavity.

25 EP-B-0690747 describes particles comprising an excipient forming a matrix and at least one active ingredient uniformly distributed in the mass of the matrix which are prepared by a process comprising the steps of preparing an homogeneous pasty mixture with a viscosity below 1 Pa.s, measured at room temperature (15-20°C), from at least one active ingredient, a physiologically acceptable hydrophilic excipient and water; extruding the resulting homogeneous mixture and cutting the extrudate to give moist particles; freezing

-10-

the resulting particles as they fall under gravity through a stream of inert gas at a temperature below 0°C; and drying the particles by freeze drying.

5 Australian Patent No. 666666 discloses a rapidly disintegratable multiparticulate tablet having a mixture of excipients in which the active substance is present in the form of coated microcrystals or optionally coated microgranules. Such tablets disintegrate in the mouth in an extremely short time, typically less than 60 seconds.

10 US Patent No. 5382437 discloses a porous carrier material having sufficient rigidity for carrying and administering an active material which is capable of rapid dissolution by saliva and which is formed by freezing a liquefied ammonia solution comprising liquid  
15 ammonia, a liquid ammonia-soluble gel or foam material and a rigidifying agent for the gel or foam material selected from the group consisting of a monosaccharide, a polysaccharide and combinations thereof, and deammoniating the frozen material thus formed by causing  
20 material transfer of ammonia from the frozen state to the gas state thereby leaving spaces in the carrier material in place of the frozen ammonia.

Published International Application No. WO 93/13758 (PCT/US92/07497) describes tablets of increased  
25 physical strength which are prepared by combining and compressing a meltable binder, excipients and a pharmaceutically active agent into a tablet, melting the binder in the tablet and then solidifying the binder. In one embodiment, a disintegrating agent is utilised to  
30 increase the disintegration rate of the tablet after oral intake. In another embodiment, a volatilisable component is used to form porous tablets. Some embodiments disintegrate in the mouth in less than 10 seconds.

US Patents Nos. 3885026 and 4134943 also disclose  
35 fast-dispersing porous tablets and a method for increasing their physical strength by first compressing the tablet and then volatilising a readily volatilisable

-11-

solid adjuvant incorporated in the tablet to attain the desired porosity.

EP-A-0601965 describes a shearform matrix material which can be used, inter alia, to deliver a pharmaceutically active agent. The shearform matrix is formed by increasing the temperature of a feedstock which includes a solid non-solubilised carrier material to the point where it will undergo internal flow with the application of a fluid shear force, ejecting a stream of the heated feedstock thus formed under pressure from an orifice and then subjecting the feedstock to disruptive fluid shear force which separates the flow of feedstock into multiple parts and transforms the morphology of the feedstock.

US Patent No. 5683720 discloses discrete particles containing a pharmaceutically active agent which can be fast-dispersing and are formed by subjecting a solid, organic feedstock to liquiflash conditions whereby the feedstock is transformed instantaneously from solid to liquiform to solid, liquiform being a transient condition in which the feedstock has substantially unimpeded internal flow. Shear force is then imparted to the liquiform feedstock in an amount sufficient to separate tiny masses of feedstock which then solidify as discrete particles.

The term "fast-dispersing dosage form" therefore encompasses, but is not limited to, all the types of dosage form described in the preceding paragraphs. However, it is particularly preferred that the fast-dispersing dosage form is of the type described in U.K. Patent No. 1548022, that is, a solid fast-dispersing dosage form comprising a network of the active ingredient and a water-soluble or water-dispersible carrier which is inert towards the active ingredient, the network having been obtained by subliming solvent from a composition in the solid state, that composition comprising the active ingredient and a solution of the carrier in a solvent.

-12-

It is preferred that the composition of the invention disintegrates within 1 to 60 seconds, more preferably 1 to 30 seconds, especially 1 to 10 seconds, and particularly 2 to 8 seconds, of being placed in the oral cavity.

In the case of the preferred type of fast-dispersing dosage form described above, the composition will preferably contain, in addition to the active ingredient, matrix forming agents and secondary components. Matrix forming agents suitable for use in the present invention include materials derived from animal or vegetable proteins, such as the gelatins, dextrans and soy, wheat and psyllium seed proteins; gums such as acacia, guar, agar, and xanthan; polysaccharides; alginates; carboxymethylcelluloses; carrageenans; dextrans; pectins; synthetic polymers such as polyvinylpyrrolidone; and polypeptide/protein or polysaccharide complexes such as gelatin-acacia complexes.

Other matrix forming agents suitable for use in the present invention include sugars such as mannitol, dextrose, lactose, galactose and trehalose; cyclic sugars such as cyclodextrin; inorganic salts such as sodium phosphate, sodium chloride and aluminium silicates; and amino acids having from 2 to 12 carbon atoms such as a glycine, L-alanine, L-aspartic acid, L-glutamic acid, L-hydroxyproline, L-isoleucine, L-leucine and L-phenylalanine.

One or more matrix forming agents may be incorporated into the solution or suspension prior to solidification. The matrix forming agent may be present in addition to a surfactant or to the exclusion of a surfactant. In addition to forming the matrix, the matrix forming agent may aid in maintaining the dispersion of any active ingredient within the solution or suspension. This is especially helpful in the case of active agents that are not sufficiently soluble in water

-13-

and must, therefore, be suspended rather than dissolved.

Secondary components such as preservatives, antioxidants, surfactants, viscosity enhancers, colouring agents, flavouring agents, pH modifiers, sweeteners or taste-masking agents may also be incorporated into the composition. Suitable colouring agents include red, black and yellow iron oxides and FD & C dyes such as FD & C blue No. 2 and FD & C red No. 40 available from Ellis & Everard. Suitable flavouring agents include mint, raspberry, liquorice, orange, lemon, grapefruit, caramel, vanilla, cherry and grape flavours and combinations of these. Suitable pH modifiers include citric acid, tartaric acid, phosphoric acid, hydrochloric acid and maleic acid. Suitable sweeteners include aspartame, acesulfame K and thaumatin. Suitable taste-masking agents include sodium bicarbonate, ion-exchange resins, cyclodextrin inclusion compounds, adsorbates or microencapsulated actives.

Preferred compositions in accordance with this invention include a 5-HT<sub>1A</sub> agonist, especially an azapirone or a salt thereof, as the active 5-HT<sub>1</sub> agonist. It is particularly preferred that the active 5-HT<sub>1</sub> agonist is buspirone or a salt thereof.

Buspirone which is absorbed by pre-gastric absorption or at a high rate across the stomach mucosa from a composition in accordance with this invention passes straight into the systemic circulatory system thereby avoiding first pass metabolism in the liver. Accordingly, the initial rapid production of unwanted, inactive metabolites is reduced and the bioavailability of active buspirone is increased. This results in a number of advantages. For instance, the increased bioavailability of active buspirone means that the dose of buspirone may be reduced whilst still producing the desired beneficial effect. This will result in a further decrease in the production of unwanted metabolites and a reduction in the incidence and/or severity of side

-14-

effects.

In the case of buspirone, the active ingredient preferably is present in the composition in an amount of from 0.5 to 30%, more preferably 1 to 20%, by weight of the composition. It is also preferred that the active  
5 ingredient is present in the composition in an amount of from 0.25 to 50 mg, more preferably 0.5 to 10 mg and, especially, 1 to 10 mg.

In the case of other 5-HT<sub>1</sub> agonists, these also  
10 will be present in concentrations which are clinically effective.

According to another aspect of the invention there is provided a process for preparing a pharmaceutical composition as defined above which  
15 comprises bringing a carrier into association with the active ingredient.

In a further aspect, the invention provides the use of a fast-dispersing dosage form designed to release active ingredient rapidly in the oral cavity to deliver a  
20 5-HT<sub>1</sub> agonist. A method of administering a 5-HT<sub>1</sub> agonist to a patient which comprises introducing into the oral cavity of the patient a composition as previously defined is also provided.

The invention also provides, in another aspect, a  
25 composition as defined above for use in the treatment of anxiety. The composition of the invention is also useful in the palliative treatment of anxiety neurosis, that is, neurosis with a preponderance of anxiety symptoms.

5-HT<sub>1</sub> agonists, especially the azapirones, have  
30 also been evaluated in the treatment of depression, attention deficit disorder and panic disorders and as memory enhancers. Also, the azapirones, especially buspirone, have been found to be useful in the treatment and/or prophylaxis of incontinence disorders associated  
35 with the gastrointestinal or urogenital tracts, such as urinary incontinence, faecal incontinence and urinary retention. Such compounds are also useful for inducing

-15-

immunosuppression and/or treating immune disorders and are therefore useful in the treatment of conditions such as contact, atopic or eczematous dermatitis and Sjogren's syndrome (including secondary keratoconjunctivitis sicca), autoimmune diseases and diseases of known or unknown etiology having an immunological component or allergies, especially rheumatoid arthritis and, in particular, juvenile rheumatoid arthritis. Such compounds may also be used in the treatment of sleep apnoea and related respiratory disorders, such as sudden infant death syndrome, and can also alleviate the symptoms of sleep apnoea such as anxiety, depression, fatigue, malaise, irritability, anger and hostility.

In addition, azapirones such as buspirone can be used in the treatment of substance addiction. In this respect, substance addiction includes over-eating, eating disorders and the habitual use of alcohol, tobacco, marijuana, cocaine, opiates, methadone, amphetamine, methphenidate and related designer drugs. Such compounds are particularly useful in the treatment of alcohol abuse as they also reduce the craving for alcohol and can therefore be used for treating patients undergoing short term treatment of alcohol withdrawal and in chronic alcohol abusers. Use of such compounds in the treatment of alcohol abuse avoids the enhancement or continuation of sensory impairment, the risk of developing drug dependence and the unpleasant effects of so-called aversion therapy. Moreover, such compounds produce behavioural modifications which include lessening of alcohol craving and ingestion and improvement of social functioning. In addition, psychogenic symptoms, such as illness, anxiety, depression, clouded sensorium, hostility, violence and decreased cognition, are alleviated.

Azapirones, particularly buspirone, are also useful for the alleviation of extrapyramidal motor disorders and can therefore be used to treat such

-16-

conditions as Parkinson's disease, neuroleptic-induced extrapyramidal symptoms and tardive dyskinesia.

In addition to the above conditions, 5-HT<sub>1</sub> agonists have also been used in the treatment of social phobia, obsessive-compulsive disorder, migraine, cerebellar ataxia, levodopa-induced dyskinesias, Huntington's disease, central and peripheral neurodegenerative disorders, emesis, hypertension, hayfever, asthma and pruritis and to assist smokers in giving up smoking.

Of the 5-HT<sub>1</sub> agonists other than the azapirones, the 5-HT<sub>1D</sub> agonists have been found to be especially useful in the treatment of migraine and related conditions.

According to a further aspect of the invention there is therefore provided the use of a composition as defined above for the manufacture of a medicament for the treatment of depression, attention deficit disorder, panic disorders, sleep apnoea and/or related respiratory disorders and/or substance addiction, especially alcohol abuse, the treatment and/or prophylaxis of incontinence disorders, inducing immunosuppression and/or treating immune disorders, the alleviation of extrapyramidal motor disorders and/or as a memory enhancer.

This invention is further illustrated by the following examples.

Example 1.

Preparation of a fast-dispersing dosage form of buspirone hydrochloride

(a) Preparation of buspirone hydrochloride 2.0% dispersion

Gelatin (720g) and mannitol (540g) were dispersed in a portion of purified water (16kg) by mixing thoroughly in the bowl of a vacuum mixer. The mix was then heated to 40°C ± 2°C and homogenised for ten minutes. The mix was

-17-

cooled down to room temperature (20-24°C). When cooled the glycine (180g) and buspirone hydrochloride (360g) was added. The mix was homogenised to ensure dissolution of glycine and the drug. Citric acid (54g) was added  
5 gradually with stirring, to adjust the solution pH to 4.0. The remaining water (146g) was added to the mixer and the bulk mix homogenised to ensure dissolution was complete.

(b) Preparation of buspirone hydrochloride 10mg units  
10 500mg of the buspirone hydrochloride 2.0% dispersion formed in (a) above was dosed into each one of a series of pre-formed blister pockets having a pocket diameter of 16mm. The blister laminate comprised 200µm PVC coated with 40gsm PVdC. The product was frozen immediately in  
15 a liquid nitrogen freeze tunnel. The frozen product was then stored below -18°C for a minimum of 40 hours prior to freeze-drying in a freeze drier using a drying temperature of +20°C and a chamber pressure of 0.5 mbar. The freeze dried units were then inspected for the  
20 presence of critical defects and the remainder of the batch sealed with lidding foil consisting of a paper/foil laminate (20µm aluminium).

Each blister was then coded with a batch number and overwrapped in a preformed sachet by placing the  
25 blister in the sachet and sealing the open end of the sachet completely. Each sachet was then labelled with the product name, batch number, date of manufacture and suppliers name.

-18-

Each dosage unit had the following composition:

	Ingredient	Weight (mg)	% by wt of composition
5	Purified Water USP/EP*	448.500	89.7
	Buspirone HCl USP	10.000	2.0
	Gelatin EP/USNF	20.000	4.0
	Mannitol EP/USP	15.000	3.0
	Glycine USP	5.000	1.0
10	Citric Acid	1.500	0.3
	Total	500.000	100.000

\*Signifies removed during the lyophilisation process.

15 Example 2

Comparative pharmacokinetic study

The aim of this experiment was to compare the bioavailability of the buspirone hydrochloride formulation of Example 1 with the commercially available  
20 tablet formulation of buspirone hydrochloride sold under the registered Trade Mark "Buspar" by Bristol-Myers Pharmaceuticals, Bristol-Myers Squibb House, 141-149 Staines Road, Hounslow, Middlesex, TW3 3JA, England.

An open label, randomised, crossover, volunteer  
25 study was performed as follows. Six fasted, healthy male subjects of ages between 18 and 40 years, giving written informed consent, underwent a thorough medical examination to establish their fitness to participate in the study. Subjects received study treatment in the  
30 order dictated by a pre-determined randomisation schedule. Subjects were given either the formulation of Example 1 or the "Buspar" formulation. Blood samples for determination of pharmacokinetic parameters were taken at baseline (immediately before drug administration), then  
35 after 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 12 and 24 hours. The study procedures were repeated two weeks later, when subjects were crossed-over to receive

-19-

their second drug administration. Buspirone hydrochloride was administered as single 20 mg doses (made up from 2 x 10 mg tablets) of the formulation of Example 1 or of the "Buspar" formulation.

5 HPLC-MS assays were performed to determine the concentration of buspirone and 1-pyrimidinylpiperazine (1-PP) in each of the blood plasma samples. The following pharmacokinetic parameters were determined for both analysed substances: bioavailability (as measured  
10 as the area under the curve (AUC) of the drug concentration/time plot) and C<sub>max</sub> (the maximum plasma concentration achieved).

The results are shown in graphical form in Figures 1 and 2 where each figure is a plot of the  
15 concentration of a specific compound in a blood plasma sample versus the time at which the sample was taken for the formulation of Example 1 (Example 1) and the tablet formulation sold under the registered Trade Mark "Buspar" (Buspar). In Figure 1, the specific compound is  
20 buspirone. In Figure 2, the specific compound is 1-pyrimidinylpiperazine (1-PP).

The mean results are shown in numerical form in Table 1 below.

25 TABLE 1

	Buspirone		1-PP	
	C <sub>max</sub> (ng/ml)	AUC <sub>(0-24hr)</sub> (ng/ml.hr)	C <sub>max</sub> (ng/ml)	AUC <sub>(0-24hr)</sub> (ng/ml.hr)
Example 1, 20 mg	13.0	33.4	6.5	46.5
Buspar 20mg	3.6	8.0	6.8	37.9

30

From Figures 1 and 2 and Table 1, it is apparent that the bioavailability of buspirone from the formulation of Example 1 is about four times that of  
35 buspirone from the "Buspar" formulation despite the fact that both formulations contained the same amount of

-20-

active ingredient. Also, the bioavailability of 1-pyrimidinylpiperazine (1-PP) is very similar for both formulations. However, in view of the much greater bioavailability of buspirone from the formulation of Example 1, it is envisaged that the dose of buspirone could be significantly reduced thereby significantly reducing the quantity of unwanted metabolites and the incidence or severity of side effects whilst still achieving the desired levels of buspirone in plasma and hence the desired therapeutic effect associated with this compound.

In Table 1, the ratio of the area under the plasma concentration-time curve (AUC) for buspirone and the AUC for 1-PP was 0.211 for the "Buspar" formulation, indicating clearly the extensive metabolism of buspirone when administered in a conventional tablet form. The corresponding AUC ratio for Example 1 in Table 1 was 0.718. This demonstrates that administration in the formulation of Example 1 results in a greater proportion of the administered dose of buspirone being absorbed in the unmetabolised form and, indeed, it is apparent from Figure 2 that metabolism of buspirone occurs more slowly for the formulation of Example 1 since the maximum amount of 1-PP for the formulation of Example 1 is observed about 2 hours later than that for the conventional "Buspar" formulation.

Pharmaceutical compositions of this invention will increase the ratio of the unchanged drug to the main metabolite's area under the plasma concentration-time curve (AUC) by at least 1.5 times and, most preferably, by at least 2 times.

#### Examples 3 to 11

The following additional fast-dispersing dosage forms may be prepared according to the method of Example

1:-

-21-

Example 3

	Ingredient	Weight (mg)	% by wt of composition
5	Purified Water EP/USP*	223.875	89.550
	Buspirone HCl	3.000	1.200
	Gelatin EP/USNF	10.000	4.000
	Mannitol EP/USP	7.500	3.000
	Glycine EP/USP	2.500	1.000
10	Banana Flavour	0.625	0.250
	Raspberry Flavour	0.625	0.250
	Aspartame EP/USNF	1.875	0.750
	Total	250.000	100.000

\*Signifies removed during the lyophilisation process.

15

Example 4

	Ingredient	Weight (mg)	% by wt of composition
20	Purified Water EP/USP*	450.750	90.150
	Buspirone HCl	3.000	0.600
	Gelatin EP/USNF	20.000	4.000
	Mannitol EP/USP	15.000	3.000
	Glycine EP/USP	5.000	1.000
	Mint Flavour	2.500	0.500
25	Aspartame EP/USNF	3.750	0.750
	Total	500.000	100.000

\*Signifies removed during the lyophilisation process.

Example 5

30

	Ingredient	Weight (mg)	% by wt of composition
	Purified Water EP/USP*	224.750	89.900
	Flesinoxan HCl	4.000	1.600
	Gelatin EP/USNF	11.250	4.500
35	Mannitol EP/USP	7.500	3.000
	Mint Flavour	1.250	0.500
	Aspartame EP/USNF	1.250	0.500
	Total	250.000	100.000

\*Signifies removed during the lyophilisation process.

40

-22-

Example 6

	Ingredient	Weight (mg)	% by wt of composition
5	Purified Water EP/USP*	666.875	88.917
	Gepirone HCl	10.000	1.333
	Gelatin EP/USNF	33.750	4.500
	Mannitol EP/USP	26.250	3.500
	Grape Flavour	3.750	0.500
10	Raspberry Flavour	3.750	0.500
	Aspartame EP/USNF	5.625	0.750
	Total	750.000	100.000

\*Signifies removed during the lyophilisation process.

15 Example 7

	Ingredient	Weight (mg)	% by wt of composition
	Purified Water EP/USP*	448.750	89.750
	Ipsapirone HCl	5.000	1.000
20	Gelatin EP/USNF	20.000	4.000
	Mannitol EP/USP	15.000	3.000
	Glycine USP	2.500	0.500
	Citric Acid EP/USP	2.500	0.500
	Liquorice Flavour	3.750	0.750
25	Aspartame EP/USNF	2.500	0.500
	Total	500.000	100.000

\*Signifies removed during the lyophilisation process.

Example 8

	Ingredient	Weight (mg)	% by wt of composition
	Purified Water EP/USP*	225.625	90.250
	Alnespirone	2.500	1.000
	Gelatin EP/USNF	11.250	4.500
35	Mannitol EP/USP	7.500	3.000
	Grapefruit Flavour	1.250	0.500
	Aspartame EP/USNF	1.875	0.750
	Total	250.000	100.000

\*Signifies removed during the lyophilisation process.

40

Example 9

	Ingredient	Weight (mg)	% by wt of composition
5	Purified Water EP/USP*	649.375	86.583
	Sumatriptan Succinate	35.000	4.667
	Gelatin EP/USNF	31.875	4.250
	Mannitol EP/USP	22.500	3.000
	Cherry Flavour	3.750	0.500
10	Aspartame EP/USNF	7.500	1.000
	Total	750.000	100.000

\*Signifies removed during the lyophilisation process.

Example 10

	Ingredient	Weight (mg)	% by wt of composition
15	Purified Water EP/USP*	225.000	90.000
	Zolmitriptan	5.000	2.000
	Gelatin EP/USNF	10.000	4.000
20	Mannitol EP/USP	7.500	3.000
	Cherry Flavour	1.250	0.500
	Aspartame EP/USNF	1.250	0.500
	Total	250.000	100.000

25 \*Signifies removed during the lyophilisation process.

Example 11

	Ingredient	Weight (mg)	% by wt of composition
30	Purified Water EP/USP*	428.750	85.750
	Oxaflozane	30.000	6.000
	Gelatin EP/USNF	20.000	4.000
	Mannitol EP/USP	15.000	3.000
	Lemon Flavour	2.500	0.500
35	Aspartame EP/USNF	3.750	0.750
	Total	500.000	100.000

\*Signifies removed during the lyophilisation process.

-24-

CLAIMS

1. A pharmaceutical composition for oral  
5 administration comprising a carrier and, as an active  
ingredient, a 5-HT<sub>1</sub> agonist, characterised in that the  
composition is formulated to reduce pre-systemic  
metabolism of said 5-HT<sub>1</sub> agonist.
- 10 2. A composition according to claim 1 in which the  
composition is formulated to promote pre-gastric  
absorption of said 5-HT<sub>1</sub> agonist.
3. A composition according to claim 1 or claim 2 in  
15 which the composition is formulated to promote absorption  
of said 5-HT<sub>1</sub> agonist through the buccal, sublingual,  
pharyngeal and/or oesophageal mucous membrane.
4. A composition according to claim 1 in which the  
20 composition is formulated to promote absorption of said  
5-HT<sub>1</sub> agonist through the stomach mucous membrane.
5. A composition according to any one of the  
preceding claims in which the 5-HT<sub>1</sub> agonist is selected  
25 from buspirone, gepirone, ipsapirone, zalospirone,  
umespirone, alnespirone, enilospirone, WY-48723, SUN-  
8399, tandospirone, flesinoxan, lesopitron, ebalzotan,  
adatanserin, LY-228729, F-8910-RS, U-93385, SL-87.0765,  
FG-5893, S-14506, EMD-56551, HT-90B, F-92502-CN, E-4414,  
30 MKC-242, F-12439, BIMT-17, LY-39, SL-88.0338, SR-57746A,  
LY-175644, A-74283, Bay-r-1531, CGS-12066B, CGP-50281,  
WAY-100012, 3a,4,4a,6a,7,7a-hexahydro-2-[4-[4-(2-  
pyrimidinyl)-1-[piperazinyl]butyl]-4,7-  
ethenocyclobuta[f]-1,2-benzisothiazol-3(2H)-one 1,1-  
35 dioxide, cis-7-chloro-10-methoxy-5a 10b-dihydro-3N-n-  
propyl-6H-indeno[1,2-d]azepine, 1-cyclohexyl-3-[4-[4-  
(2,3-dihydro-2,2-dimethylbenzofuran-7-yl)-1-piperazinyl]-

-25-

1-butyl]-2-imidazolidinone, 1-[3-amino-2H-1-benzopyran-2-one-8-yl]piperazine, oxaflozane, RU-5031, CP-93129, naratriptan, avitriptan, rizatriptan, L-694247, IS-159, almotriptan, zolmitriptan, sumatriptan, eletriptan,  
5 VML-251, L-0076, ALX-0625, CP-122288, VS-395, L-747201, LY-334370 and salts thereof.

6. A composition according to any one of the preceding claims in which the 5-HT<sub>1</sub> agonist is a 5-HT<sub>1A</sub> agonist.  
10

7. A composition according to claim 6 in which the 5-HT<sub>1</sub> agonist is selected from buspirone, gepirone, ipsapirone, zalospirone, umespirone, alnespirone,  
15 enilospirone, WY-48723, SUN-8399, tandospirone and salts thereof.

8. A composition according to claim 7 in which the 5-HT<sub>1</sub> agonist is buspirone or a salt thereof.  
20

9. A composition according to any one of the preceding claims in which the active ingredient is present in an amount of from 0.5 to 30% by weight of the composition.  
25

10. A composition according to any one of the preceding claims in which the active ingredient is present in an amount of 0.25 to 50 mg.

11. A composition according to any one of the preceding claims in which the composition is in the form of a viscous emulsion, syrup or elixir, a sublingual tablet, a suckable or chewable tablet, softgel, lozenge, aqueous or non-aqueous drops or other dosage form  
35 designed to release the active ingredient in a controlled manner to saliva or to the buccal, pharyngeal and/or oesophageal mucous membranes, a fast-dispersing dosage

-26-

form designed rapidly to release the active ingredient in the oral cavity, or a bioadherent system.

12. A composition according to claim 11, in which the  
5 composition is in the form of a solid fast-dispersing  
dosage form comprising a network of the active ingredient  
and a water-soluble or water-dispersible carrier which is  
inert towards the active ingredient, the network having  
been obtained by subliming solvent from a composition in  
10 the solid state, that composition comprising the active  
ingredient and a solution of the carrier in a solvent.

13. A composition according to claim 11 or claim 12,  
in which the composition disintegrates within 1 to 10  
15 seconds of being placed in the oral cavity.

14. A pharmaceutical composition for oral  
administration comprising a carrier, and buspirone as an  
active ingredient, characterised in that the composition  
20 is in the form of a solid fast-dispersing dosage form  
comprising a network of buspirone and a water-soluble or  
water-dispersible carrier which is inert towards  
buspirone, the network having been obtained by subliming  
solvent from a composition in the solid state, that  
25 composition comprising buspirone and a solution of the  
carrier in a solvent.

15. A pharmaceutical composition for oral  
administration comprising buspirone in a solid fast-  
30 dispersing dosage form which disintegrates within 1 to 10  
seconds of being placed in the oral cavity.

16. A composition as defined in any one of the preceding  
claims for use in the treatment of anxiety.

35

17. Use of a composition as defined in any one of claims  
1 to 15 for the manufacture of a medicament for the

-27-

treatment of depression.

18. Use of a composition as defined in any one of  
claims 1 to 15 for the manufacture of a medicament for  
5 the treatment of Attention Deficit Disorder With or  
Without Hyperactivity.

19. Use of a composition as defined in any one of  
claims 1 to 15 for the manufacture of a medicament for  
10 the treatment of panic disorders.

20. Use of a composition as defined in any one of  
claims 1 to 15 for the manufacture of a medicament for  
use as a memory enhancer.

15 21. Use of a composition as defined in any one of  
claims 1 to 15 for the manufacture of a medicament for  
the palliative treatment of anxiety neurosis.

20 22. Use of a composition as defined in any one of  
claims 1 to 15 for the manufacture of a medicament for  
the treatment and/or prophylaxis of incontinence  
disorders.

25 23. Use of a composition as defined in any one of  
claims 1 to 15 for the manufacture of a medicament for  
inducing immunosuppression and/or treating immune  
disorders.

30 24. Use of a composition as defined in any one of  
claims 1 to 15 for the manufacture of a medicament for  
the treatment of sleep apnoea and/or related respiratory  
disorders.

35 25. Use of a composition as defined in any one of  
claims 1 to 15 for the manufacture of a medicament for  
the treatment of substance addiction.

-28-

26. Use of a composition as defined in any one of claims 1 to 15 for the manufacture of a medicament for the treatment of alcohol abuse.
- 5 27. Use of a composition as defined in any one of claims 1 to 15 for the manufacture of a medicament for the alleviation of extrapyramidal motor disorders.
28. A process for preparing a pharmaceutical  
10 composition according to any one of claims 1 to 16 which comprises bringing a carrier into association with said active ingredient.
29. Use of a fast-dispersing dosage form designed to  
15 release active ingredient rapidly in the oral cavity to deliver a 5-HT<sub>1</sub> agonist.

Figure 1: Mean Plasma Buspirone Levels (ng/ml)





Figure 2: Mean Plasma 1-PP Levels (ng/ml)



# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00885

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K31/505 A61K31/445 A61K31/435 A61K31/495 A61K9/00

According to International Patent Classification(IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 0, no. 0 & JP 63 250318 A (FUJIMOTO SEIYAKU KK), 18 October 1988 see abstract	1-3,5-8, 11,28
X	US 5 246 710 A (AYER) 21 September 1993  * whole document, especially column 3 lines 1-50, examples 9 and 10 and claims *	1-3,5-7, 11,16, 17,28
X	US 5 246 711 A (AYER) 21 September 1993  see claim 1 see examples 9,10	1-3,5-7, 11,16, 17,28
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

10 August 1998

Date of mailing of the international search report

09/09/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Hoff, P

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00885

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 431 922 A (NICKLASSON) 11 July 1995 see the whole document ---	1,5-10, 16,17,28
X	EP 0 313 535 A (AKTIEBOLAGET ASTRA) 26 April 1989 see the whole document ---	1,5-10, 16,28
X	EP 0 629 402 A (BAYER) 21 December 1994 see page 2 see page 3, line 1 - line 16 see page 4, line 10 see page 5, line 4 - line 34 see page 16 * claims * ---	1,5-7, 16,17,19
X	EP 0 354 777 A (GLAXO GROUP LIMITED) 14 February 1990 * page 2, lines 14-16, lines 53-54 * * page 3, lines 13-31, lines 56-59 * see page 10 - page 11 ---	1-3,6, 11,28
A	DATABASE WPI Week 9304 Derwent Publications Ltd., London, GB; AN 93-032652 XP002040477 see abstract & JP 04 360 826 A (BAYER YAKUHIN KK) 14 December 1992 see abstract ---	1,5-7,9, 10,28
A	GB 1 548 022 A (J.K. EMERSON GREGORY) 4 July 1979 cited in the application see the whole document ---	12-15
A	EP 0 546 593 A (GLAXO GROUP LIMITED) 16 June 1993 see page 2, line 35 - line 58 see page 3 - column 5 ---	12-15,29
A	US 5 478 572 A (S.T. DAVID) 26 December 1995 see the whole document ---	1,5,6, 11,16
A	US 5 169 638 A (A. DENNIS) 8 December 1992 see column 3, line 17 - line 18 see column 4, line 35 see claims 1,11 ---	1,4-8,28
	--- -/--	

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00885

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ROUGE: "Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery"</p> <p>INT. J. PHARMACEUTICS, vol. 136, no. 1-2, 1996, pages 117-139, XP002040474 see page 129 - page 131, left-hand column</p>	4
A	<p>TAY: "The site of gastrointestinal absorption of gepirone in humans"</p> <p>J. CLIN. PHARMACOL., vol. 32, September 1992, pages 827-832, XP002040475 see the whole document</p>	4-7
A	<p>YU: "Oral cavity absorption of (R)-8-hydroxy-2-(di-n-propylamino)tetralin and (s)-8-acetyl-2-(di-n-propylamino)tetralin in the rat"</p> <p>J. PHARM. PHARMACOL., vol. 48, no. 1, January 1996, pages 41-45, XP002040476 see abstract * page 44, left column, last 4 lines and right column *</p>	1-3,6
A	<p>EP 0 220 696 A (BRISTOL-MYERS COMPANY) 6 May 1987 see the whole document</p>	16,19
A	<p>EP 0 276 536 A (BRISTOL-MYERS COMPANY) 3 August 1988 see the whole document</p>	20
P,X	<p>WO 98 02186 A (FARMAC NEDERLAND BV ;DYER ALISON MARGARET (ZA); PENKLER LAWRENCE) 22 January 1998 see abstract see page 5, paragraph 2 - page 6, paragraph 4 see page 9, paragraph 4 - page 10, paragraph 2; claims; examples 3,4</p>	1-3,5, 9-13,16, 28,29
X	<p>US 5 288 497 A (STANLEY THEODORE H ET AL) 22 February 1994  see the whole document, in particular claims 1-27,167,214</p>	1-3,5, 9-11,16, 28
X	<p>US 5 288 498 A (STANLEY THEODORE H ET AL) 22 February 1994  see the whole document, in particular claims 1-14,154,200</p>	1-3,5, 9-11,16, 28
	-/--	

# INTERNATIONAL SEARCH REPORT

II. national Application No

PCT/GB 98/00885

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 96 06842 A (PFIZER LTD ;PFIZER RES &amp; DEV (IE); PFIZER (US); HARDING VALERIE DE) 7 March 1996</p> <p>see abstract see page 2, line 2 - line 23 see page 9, line 3 - line 20; claims 1,6-16; example 6</p>	<p>1-3,5, 9-13,16, 17,21, 25-29</p>
X	<p>EP 0 749 962 A (LILLY CO ELI) 27 December 1996</p> <p>see abstract see page 4, line 33 - line 39 see page 66, line 26 - line 46; claims</p>	<p>1-3,5, 9-11, 16-28</p>
X	<p>EP 0 705 600 A (LILLY CO ELI) 10 April 1996</p> <p>see abstract see page 17, line 34 - line 54; claims</p>	<p>1-3,5, 9-11,16, 28</p>
X	<p>WO 94 25023 A (PFIZER) 10 November 1994</p> <p>see abstract see page 3, line 20 - line 29 see page 5, line 1 - line 33; claims</p>	<p>1-3,5, 9-11,16, 17,21, 25-28</p>
X	<p>WO 94 14772 A (SMITHKLINE BEECHAM PLC ;BORRETT GARY THOMAS (GB); KITTERINGHAM JOH) 7 July 1994</p> <p>see abstract see page 8, line 20 - line 22; claims see page 6, line 34 - page 7, line 24</p>	<p>1-3,5, 9-11,16, 28</p>

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00885

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5246710	A	21-09-1993	US 5185158 A	09-02-1993
			US 5330762 A	19-07-1994
			US 5688518 A	18-11-1997
			US 5246711 A	21-09-1993
US 5246711	A	21-09-1993	US 5185158 A	09-02-1993
			US 5330762 A	19-07-1994
			US 5688518 A	18-11-1997
			US 5246710 A	21-09-1993
US 5431922	A	11-07-1995	NONE	
EP 313535	A	26-04-1989	AT 108997 T	15-08-1994
			AU 604585 B	20-12-1990
			AU 2623688 A	23-05-1989
			CY 1814 A	20-10-1995
			DE 3850844 D	01-09-1994
			DE 3850844 T	08-12-1994
			DK 294489 A	15-06-1989
			ES 2056955 T	16-10-1994
			FI 893017 A	20-06-1989
			HK 21295 A	24-02-1995
			IE 64705 B	23-08-1995
			JP 2501744 T	14-06-1990
			JP 2674170 B	12-11-1997
			KR 9704906 B	08-04-1997
			MX 9203372 A	01-09-1992
			PT 88820 B	29-01-1993
			WO 8903676 A	05-05-1989
			SG 144094 G	13-01-1995
EP 629402	A	21-12-1994	DE 4319760 A	22-12-1994
			AU 6345794 A	22-12-1994
			CA 2125620 A	16-12-1994
			CN 1099263 A	01-03-1995
			CZ 9401464 A	18-01-1995
			FI 942803 A	16-12-1994
			HU 70759 A	30-10-1995
			JP 6345649 A	20-12-1994
			NO 942228 A	16-12-1994

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00885

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 629402	A		NZ 260732 A	27-02-1996
			PL 303822 A	09-01-1995
			SK 72494 A	12-04-1995
			ZA 9404187 A	08-02-1995
EP 354777	A	14-02-1990	AU 3945589 A	15-02-1990
			DE 68908040 T	18-11-1993
			DK 391289 A	11-02-1990
			FI 893751 A	11-02-1990
			JP 2091068 A	30-03-1990
			PT 91417 A,B	08-03-1990
			US 5036078 A	30-07-1991
GB 1548022	A	04-07-1979	AU 513845 B	08-01-1981
			AU 2882577 A	22-03-1979
			BE 859291 A	30-03-1978
			CA 1083042 A	05-08-1980
			CH 633717 A	31-12-1982
			CY 1129 A	19-02-1982
			DE 2744493 A	13-04-1978
			FR 2366835 A	05-05-1978
			HK 58081 A	04-12-1981
			JP 1446344 C	30-06-1988
			JP 53044619 A	21-04-1978
			JP 62050445 B	24-10-1987
			JP 1509556 C	26-07-1989
			JP 61118314 A	05-06-1986
			JP 63052008 B	17-10-1988
			KE 3171 A	18-12-1981
			LU 78259 A	09-06-1978
			NL 7710876 A,B,	10-04-1978
			US 4371516 A	01-02-1983
			ZA 7705465 A	25-04-1979
EP 546593	A	16-06-1993	AU 666880 B	29-02-1996
			AU 2746992 A	06-05-1993
			BE 1005490 A	10-08-1993
			CA 2081709 A	01-05-1993
			CH 685536 A	15-08-1995
			DE 69222006 D	09-10-1997

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00885

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 546593 A		DE 69222006 T	22-01-1998
		ES 2106818 T	16-11-1997
		FR 2683146 A	07-05-1993
		GB 2262445 A,B	23-06-1993
		IT 1263253 B	05-08-1996
		JP 5194188 A	03-08-1993
		LU 88186 A	17-05-1993
		MX 9206236 A	01-04-1993
		NZ 244921 A	27-04-1995
		US 5425950 A	20-06-1995
		ZA 9208359 A	13-08-1993
US 5478572 A	26-12-1995	AU 3043895 A	21-03-1996
		CN 1128142 A	07-08-1996
		CZ 9502275 A	13-03-1996
		EP 0700680 A	13-03-1996
		FI 954154 A	07-03-1996
		HU 73182 A	28-06-1996
		JP 8183736 A	16-07-1996
		NO 953212 A	07-03-1996
		NZ 272855 A	26-05-1997
		PL 310298 A	18-03-1996
		SG 30436 A	01-06-1996
		ZA 9507144 A	26-03-1996
US 5169638 A	08-12-1992	AT 161171 T	15-01-1998
		AU 660193 B	15-06-1995
		AU 2716792 A	29-04-1993
		CA 2081070 A	24-04-1993
		DE 69223588 D	29-01-1998
		DE 69223588 T	25-06-1998
		DK 539059 T	26-01-1998
		EP 0539059 A	28-04-1993
		ES 2109986 T	01-02-1998
		FI 924831 A	24-04-1993
		JP 5194195 A	03-08-1993
		MX 9205920 A	01-06-1993
		NZ 244517 A	26-10-1994
		ZA 9207433 A	07-04-1993

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00885

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 220696	A	06-05-1987	US 4634703 A	06-01-1987
			AU 592121 B	04-01-1990
			AU 6424586 A	30-04-1987
			CY 1786 A	20-10-1995
			DE 3688038 A	22-04-1993
			ES 2053429 T	01-08-1994
			GR 3007393 T	30-07-1993
			HK 87094 A	02-09-1994
			JP 1939806 C	09-06-1995
			JP 6067841 B	31-08-1994
			JP 62111924 A	22-05-1987
EP 276536	A	03-08-1988	US 4687772 A	18-08-1987
			DE 3780618 A	27-08-1992
			EP 0276543 A	03-08-1988
			JP 1723033 C	24-12-1992
			JP 4005648 B	03-02-1992
			JP 63101324 A	06-05-1988
WO 9802186	A	22-01-1998	AU 3455197 A	09-02-1998
			AU 3455297 A	09-02-1998
			WO 9802187 A	22-01-1998
US 5288497	A	22-02-1994	CA 1338978 A	11-03-1997
			US 4671953 A	09-06-1987
			AT 129148 T	15-11-1995
			AU 668004 B	18-04-1996
			AU 5521894 A	28-04-1994
			AU 645265 B	13-01-1994
			AU 6287790 A	08-04-1991
			CA 2066423 A	06-03-1991
			DE 69023143 D	23-11-1995
			DE 69023143 T	28-03-1996
			DK 490916 T	04-03-1996
			EP 0490916 A	24-06-1992
			EP 0630647 A	28-12-1994
			ES 2077686 T	01-12-1995
			JP 2717024 B	18-02-1998
			JP 5503917 T	24-06-1993
			WO 9103237 A	21-03-1991

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00885

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5288497 A		US 5783207 A	21-07-1998
		US 5785989 A	28-07-1998
		AT 116131 T	15-01-1995
		CA 1271421 A	10-07-1990
		CA 1339190 A	29-07-1997
		DE 3650189 D	09-02-1995
		DE 3650189 T	04-05-1995
		EP 0200490 A	05-11-1986
		EP 0487520 A	03-06-1992
		EP 0490891 A	24-06-1992
		EP 0404205 A	27-12-1990
		US 4863737 A	05-09-1989
		US 4885173 A	05-12-1989
		WO 9103099 A	07-03-1991
		WO 9103234 A	21-03-1991
		US 5484602 A	16-01-1996
		US 5132114 A	21-07-1992
		US 5122127 A	16-06-1992
		US 5288498 A	22-02-1994
US 5288498 A	22-02-1994	CA 1338978 A	11-03-1997
		US 4671953 A	09-06-1987
		AT 138562 T	15-06-1996
		AU 642664 B	28-10-1993
		AU 6337190 A	08-04-1991
		CA 2066403 A	06-03-1991
		DE 69027216 D	04-07-1996
		DE 69027216 T	17-10-1996
		DK 490944 T	21-10-1996
		EP 0490944 A	24-06-1992
		ES 2089027 T	01-10-1996
		JP 2749198 B	13-05-1998
		JP 5500058 T	14-01-1993
		WO 9103236 A	21-03-1991
		AT 116131 T	15-01-1995
		CA 1271421 A	10-07-1990
		CA 1339190 A	29-07-1997
		DE 3650189 D	09-02-1995
		DE 3650189 T	04-05-1995
		EP 0200490 A	05-11-1986

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00885

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5288498 A		EP 0487520 A	03-06-1992
		EP 0490891 A	24-06-1992
		EP 0404205 A	27-12-1990
		US 4863737 A	05-09-1989
		US 4885173 A	05-12-1989
		WO 9103099 A	07-03-1991
		WO 9103234 A	21-03-1991
		US 5484602 A	16-01-1996
		US 5132114 A	21-07-1992
		US 5122127 A	16-06-1992
		US 5288497 A	22-02-1994
		US 5783207 A	21-07-1998
		US 5785989 A	28-07-1998
WO 9606842 A	07-03-1996	AP 576 A	20-03-1997
		AT 163182 T	15-02-1998
		AU 691005 B	07-05-1998
		AU 2735295 A	22-03-1996
		BG 101250 A	30-09-1997
		BR 9503812 A	16-04-1996
		CA 2198599 A	07-03-1996
		DE 69501620 D	19-03-1998
		DE 69501620 T	02-07-1998
		DK 776323 T	30-03-1998
		EP 0776323 A	04-06-1997
		ES 2112650 T	01-04-1998
		FI 970800 A	26-02-1997
		HR 950460 A	31-08-1997
		HU 77310 A	30-03-1998
		JP 9512283 T	09-12-1997
		LV 11800 A	20-06-1997
		LV 11800 B	20-10-1997
		NO 970861 A	26-02-1997
		PL 318319 A	09-06-1997
		SI 9520091 A	28-02-1998
EP 0749962 A	27-12-1996	NONE	
EP 0705600 A	10-04-1996	US 5698571 A	16-12-1997
		AU 688168 B	05-03-1998

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00885

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0705600 A		AU 3999695 A	02-05-1996
		CA 2159767 A	06-04-1996
		CZ 9700930 A	17-09-1997
		JP 8208516 A	13-08-1996
		NO 971487 A	02-04-1997
		WO 9611006 A	18-04-1996
WO 9425023 A	10-11-1994	AP 486 A	16-04-1996
		AU 689469 B	02-04-1998
		AU 6436094 A	21-11-1994
		BG 100093 A	30-04-1996
		BR 9406435 A	09-01-1996
		CA 2161533 A	10-11-1994
		CN 1121689 A	01-05-1996
		CZ 9502802 A	17-04-1996
		EP 0696194 A	14-02-1996
		HU 73670 A	30-09-1996
		JP 8504829 T	28-05-1996
		NO 954287 A	26-10-1995
		PL 311266 A	05-02-1996
		SG 43951 A	14-11-1997
		SK 133295 A	08-01-1997
		US 5545644 A	13-08-1996
		US 5559129 A	24-09-1996
		US 5559246 A	24-09-1996
		US 5578612 A	26-11-1996
		US 5607951 A	04-03-1997
		ZA 9402805 A	23-10-1995
WO 9414772 A	07-07-1994	AU 2851797 A	16-10-1997
		AU 688748 B	19-03-1998
		AU 5814594 A	19-07-1994
		CA 2152630 A	07-07-1994
		CN 1095712 A	30-11-1994
		EP 0674621 A	04-10-1995
		JP 8504790 T	21-05-1996
		MX 9400035 A	29-07-1994
		NZ 259363 A	20-12-1996
		NZ 299232 A	24-06-1997
		US 5618947 A	08-04-1997

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/00885

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9414772 A		US 5650426 A	22-07-1997
		ZA 9309457 A	19-06-1995
-----			